DocGo Inc

DocGo Inc has a market capitalization of $58.39 million and a price-to-book ratio of 0.41, indicating a significant discount to its book value. The company's liquidity position is strong, with a current ratio of 2.26 and $51.02 million in cash and equivalents, which provides a buffer against short-term obligations. However, the company's free cash flow is negative at -$188.14 million, driven by a large capital expenditure of -$7.43 million and a net loss of -$182.40 million.

Profitability metrics show a challenging operating environment for DocGo. The company reported a net loss of -$182.40 million and an operating loss of -$183.03 million, resulting in a return on equity of -126.66% and a return on assets of -84.02%. These figures are significantly below the industry median for healthcare facilities and services, which typically report positive returns on equity and assets. The gross profit margin of 30.65% is also below the industry median, indicating inefficiencies in cost management or pricing power.

DocGo's revenue is concentrated in a single business segment, pharmaceuticals, which accounts for the entirety of its $322.20 million in revenue. There is no geographic diversification disclosed, suggesting a high concentration risk in its primary market. This lack of diversification could expose the company to regional economic downturns or regulatory changes that could impact its operations.

Looking ahead, DocGo's revenue is expected to remain under pressure. The company's free cash flow is projected to remain negative, and its operating cash flow of $34.45 million is insufficient to cover its capital expenditures and net losses. Analysts have provided a mean price target of $2.10, with a median of $2.50, suggesting a potential upside from the current market price of $0.59. However, the company's financial performance and cash flow challenges may limit its ability to meet these targets in the near term.

The risk assessment for DocGo indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's high debt-to-equity ratio of 0.12 and negative net income suggest potential financial instability. The risk of dilution is low, but the company's negative free cash flow and high capital expenditures could necessitate additional financing in the future.

Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial performance and cash flow challenges remain the primary focus for investors and analysts.